Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar;128:155118. doi: 10.1016/j.metabol.2021.155118

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Fig. 5 — Rate of appearance of cortisol and corticosterone in whole body, adipose tissue and skeletal muscle. Data are mean ± SEM. Whole body rate of appearance (Ra) of cortisol (A) and corticosterone (B) (both n = 14) were compared in placebo (unbroken line) and probenecid (dashed line) phases at time points 0–360 min. Potassium canrenoate (K Can) increased Ra cortisol and corticosterone during the placebo phase (both p < 0.001). Probenecid increased Ra cortisol but not corticosterone following RU486. There was detectable cortisol (C) but not corticosterone (D) generation across adipose tissue (both n = 7) but only in the pre-drug period (p < 0.05 vs zero). Probenecid did not alter Ra cortisol or Ra corticosterone across adipose. There was detectable Ra cortisol (E) and Ra corticosterone (F) across skeletal muscle (both n = 14) throughout the study period which was unaltered by probenecid.